TRACON Pharmaceuticals Inc (NASDAQ:TCON) has a beta value of 0.78 and has seen 6.54 million shares traded in the last trading session. The company, currently valued at $17.06M, closed the last trade at $0.38 per share which meant it lost -$0.06 on the day or -14.31% during that session. The TCON stock price is -476.32% off its 52-week high price of $2.19 and 65.79% above the 52-week low of $0.13. If we look at the company’s 10-day average daily trading volume, we find that it stood at 9.78 million shares traded. The 3-month trading volume is 2.94 million shares.
TRACON Pharmaceuticals Inc (NASDAQ:TCON) trade information
Sporting -14.31% in the red in last session, the stock has traded in the green over the last five days, when the TCON stock price touched $0.38 or saw a rise of 48.46%. Year-to-date, TRACON Pharmaceuticals Inc shares have moved 114.16%, while the 5-day performance has seen it change 51.82%. Over the past 30 days, the shares of TRACON Pharmaceuticals Inc (NASDAQ:TCON) have changed 97.37%. Short interest in the company has seen 0.45 million shares shorted with days to cover at 0.67.
TRACON Pharmaceuticals Inc (TCON) estimates and forecasts
Figures show that TRACON Pharmaceuticals Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 53.31% over the past 6 months, with this year growth rate of -81.82%, compared to 13.60% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are 83.30% and 75.00% for the next quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 61.51% over the past 5 years.
TCON Dividends
TRACON Pharmaceuticals Inc is expected to release its next earnings report between May 08 and May 13 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
TRACON Pharmaceuticals Inc (NASDAQ:TCON)’s Major holders
Insiders own 5.00% of the company shares, while shares held by institutions stand at 11.87% with a share float percentage of 12.50%. Investors are also buoyed by the number of investors in a company, with TRACON Pharmaceuticals Inc having a total of 29 institutions that hold shares in the company. The top two institutional holders are Opaleye Management Inc. with over 4.76 million shares worth more than $1.39 million. As of Jun 29, 2023, Opaleye Management Inc. held 15.52% of shares outstanding.
The other major institutional holder is Ikarian Capital, LLC, with the holding of over 2.77 million shares as of Jun 29, 2023. The firm’s total holdings are worth over $0.8 million and represent 9.01% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Jun 29, 2023, the former fund manager holds about 1.56% shares in the company for having 0.48 million shares of worth $0.14 million while later fund manager owns 0.26 million shares of worth $76466.0 as of Jun 29, 2023, which makes it owner of about 0.86% of company’s outstanding stock.
